Top

Osteoporosis International

Published in:

01-03-2009 | Original Article

Design of the POSSIBLE US™ Study: postmenopausal women’s compliance and persistence with osteoporosis medications

Authors: E. Barrett-Connor, K. Ensrud, A. N. A. Tosteson, S. F. Varon, M. Anthony, N. Daizadeh, S. Wade

Published in: Osteoporosis International | Issue 3/2009

Abstract

Summary

Failure to take prescribed medication is common. The POSSIBLE US™ study is evaluating the impact of physician and patient characteristics on patient-reported compliance and persistence with osteoporosis medications. We report our study design and the baseline characteristics of 4,994 postmenopausal women recruited from primary care physician offices in 33 states.

Introduction

The Prospective Observational Scientific Study Investigating Bone Loss Experience (POSSIBLE US™) is a longitudinal cohort study of osteoporosis therapy in primary care.

Methods

Between 2004 and 2007, 134 physicians (in 33 states) enrolled postmenopausal women initiating, changing, or continuing osteoporosis medications. After completing a baseline questionnaire, participants will provide data semi-annually for up to 3 years through 2008. Physicians provide patient data at baseline and routine follow-up visits. Participants from 23 sites also signed a release regarding administrative claims data for economic analyses and validation of self-reported data.

Baseline results

Four thousand nine hundred and ninety-four evaluable women were recruited from internal medicine (n = 1,784), family practice (n = 1,556), obstetrics/gynecology (n = 1,556), and from one rheumatology practice (n = 98). Mean participant age was 64.3 years (SD = 9.97); 89% were Caucasian; 59% had some college education. Sixty-three percent used a single osteoporosis agent, usually a bisphosphonate. For monotherapy patients, concordance between clinic- and patient-reported medication use was lowest for patients prescribed estrogen therapy (70%) or calcium/vitamin D (72%). Obstetrician/gynecologists enrolled younger women, who were more likely to use estrogen therapy than patients enrolled by other physicians. The 934 women (19%) prescribed only calcium/vitamin D were younger than women prescribed pharmacologic therapy.

Conclusions

POSSIBLE US™ provides a unique foundation for evaluating longitudinal use of osteoporosis medications and related outcomes.

Adachi JD (1996) Current treatment options for osteoporosis. J Rheumatol Suppl 45:11–14PubMed

Recker RR, Gallager R, MacCosbe PE (2005) Effect of dosing frequency on bisphosphonates medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80:856–861PubMedCrossRef

Caro JJ, Ishak KJ, Huybrechts KF et al (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003–1008PubMedCrossRef

McCombs JS, Thiebaud P, McLaughlin-Miley C et al (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271–287PubMedCrossRef

Yood RA, Emani S, Reed JI et al (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14:965–968PubMedCrossRef

Lo JC, Pressman AR, Omar MA, Ettinger B (2006) Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 17:922–928PubMedCrossRef

Weycker D, Macarios D, Edelsberg J, Oster G (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 17:1645–1652PubMedCrossRef

Gold DT (2006) Medication adherence: a challenge for patients with postmenopausal osteoporosis and other chronic illnesses. J Manag Care Pharm 12(6) [Suppl A]:S20–S25PubMed

Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023–1031PubMedCrossRef

10.

Siris ES, Harris ST, Rosen CJ et al (2006) Adherence to bisphosphonates therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022PubMedCrossRef

11.

Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922–928PubMedCrossRef

12.

Hamilton B, McCoy K, Taggart H (2003) Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 14:259–262PubMed

13.

Segal E, Tamir A, Ish-Shalom S (2003) Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J 5:859–862PubMed

14.

Carnevale V, Nieddu L, Romagnoli E et al (2006) Osteoporosis intervention in ambulatory patients with previous hip fracture: a multicentric, nationwide Italian survey. Osteoporos Int 17:478–483PubMedCrossRef

15.

Rossini M, Bianchi G, Di Munno O et al (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17:914–921PubMedCrossRef

16.

Stafford RS, Drieling RL, Hersh AL (2004) National trends in osteoporosis visits and osteoporosis treatment, 1988–2003. Arch Intern Med 164:1525–1530PubMedCrossRef

17.

Turbi C, Herrero-Beaumont G, Acebes JC et al (2004) Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 26:245–256PubMedCrossRef

18.

Curtis JR, Westfall AO, Allison JJ et al (2006) Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users. Osteoporosis Int 17:1268–1274CrossRef

19.

Downey TW, Foltz SH, Boccuzzi SJ et al (2006) Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J 99:570–575PubMedCrossRef

20.

Silverman SL, Watts NB, Delmas PD et al (2007) Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 18:25–34PubMedCrossRef

21.

Atkinson M, Sinha A, Hass SL et al (2004) Validation of general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medications (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2:12PubMedCrossRef

22.

Brooks R (1996) EuroQol: The current state of play. Health Policy 37:53–72PubMedCrossRef

23.

Silverman SL (2000) The osteoporosis assessment questionnaire (OPAQ): a reliable and valid disease-targeted measure of health related quality of life (HRQOL) in osteoporosis. Qual Life Res 9:767–774CrossRef

24.

Siris ES, Miller P, Barrett-Connor E et al (1998) Design of NORA, the National Osteoporosis Risk Assessment Program: a longitudinal US registry of postmenopausal women. Osteoporos Int 8 [Suppl 1]:S62–S69PubMed

25.

Weiss TW, Siris ES, Barrett-Connor E et al (2007) Osteoporosis practice patterns in 2006 among primary care physicians participating in the NORA study. Osteoporos Int 18:1473–1480PubMedCrossRef

Title: Design of the POSSIBLE US™ Study: postmenopausal women’s compliance and persistence with osteoporosis medications
Authors: E. Barrett-Connor
K. Ensrud
A. N. A. Tosteson
S. F. Varon
M. Anthony
N. Daizadeh
S. Wade
Publication date: 01-03-2009
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 3/2009
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-008-0674-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Design of the POSSIBLE US™ Study: postmenopausal women’s compliance and persistence with osteoporosis medications

Abstract

Summary

Introduction

Methods

Baseline results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Methods

Baseline results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2009

Osteoporotic fractures and hospitalization risk in chronic spinal cord injury

Bone mass and microarchitecture of irradiated and bone marrow-transplanted mice: influences of the donor strain

Management of osteoporosis in primary care in Australia

Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science

Physical activity and dietary calcium interactions in bone mass in Scottish postmenopausal women

Reviewers 2008